September 25, 2012
Warnex Addresses Annual Meeting Date
Laval, Quebec, September 25, 2012 - On June 22, 2012, Warnex Inc. (TSXV:WNX) ("Warnex" or the "Company") announced that it had received court approval to delay the date of its Annual Meeting to a date which was to be no later than September 30, 2012. Such delay was precipitated by the fact that as Warnex was advancing in its strategic review process, it realized that such process may result in the requirement to present various matters to its shareholders for approval, and that it would be preferable that Warnex allow for the possibility of combining its Annual Meeting with any other meeting of shareholders that may be required.
As Warnex continues to advance in its strategic review process, it has come to the determination that it would be in the best interests of the Company to further extend the deadline for the holding of its Annual Meeting to December 31, 2012. Accordingly, Warnex has obtained court approval to so extend such deadline. A copy of such court approval may be obtained from Warnex upon request.
However, Warnex cautions that there can be no assurance that its ongoing strategic review process will result in any transaction, or, if a transaction is realized, as to its terms or timing. Warnex's immediate priority remains ensuring that its Bioanalytical division continues to maintain the highest standards of service delivery for the benefit of its customers, its employees and its other stakeholders.
Further announcements regarding the date for Warnex's Annual Meeting will be made at the appropriate time.
Warnex (www.warnex.ca) is a life sciences company which, operating out of facilities located in Laval, Quebec, specializes in bioequivalence and bioavailability studies for clinical trials.
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
Certain statements contained in this news release are forward-looking and are subject to numerous risks and uncertainties, known and unknown. For further information identifying known risks and uncertainties, relating to financial resources, liquidity risk, key customers and business partners, credit risk, foreign currency risk, government regulations, laboratory facilities, volatility of share price, employees, suppliers, and other important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the heading Risks and Uncertainties in Warnex's most recent Management's Discussion and Analysis, which can be found at www.sedar.com. Consequently, actual results may differ materially from the anticipated results expressed in these forward-looking statements.
For more information, please contact:
Chairman of the Board of Directors, Warnex Inc.
Tel: (514) 940-3610